Objective To investigate the clinicopathological features and prognosis of perimenopausal patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive and human epidermal growth factor receptor 2 (HER2) negative (ER/PR⁺HER2^-) invasive breast cancer. Methods A total of 335 patients with ER/PR⁺HER2^- invasive breast cancer who were admitted to the Huangpu Branch of Shanghai Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine from Jan. to Dec. 2009 were included and divided into premenopausal group (<40 years, 23 cases), perimenopausal group (40-60 years, 228 cases) and postmenopausal group (>60 years, 84 cases) according to the menopausal statuses. The clinicopathological features and prognosis of the patients in the 3 groups were compared, and the prognostic risk factors for the patients were investigated using univariate and multivariate Cox regression analyses. Results There were no significant differences in tumor T stage, N stage, TNM stage, histological grade, histological classification, lymphovascular invasion or PR expression level of the ER/PR⁺HER2^- invasive breast cancer patients with different menopausal statuses (all P>0.05). There were significant differences in the expression of Ki-67, ER, and P53 among the 3 groups (all P<0.01). The proportions of patients with Ki-67 positive cells ≥ 60% and ≥ 20% were higher in the perimenopausal and premenopausal groups than in the postmenopausal group. The expression levels of ER in the premenopausal, perimenopausal and postmenopausal groups were increased in turn. The expression levels of P53 in the perimenopausal and premenopausal groups were higher than that in the postmenopausal group. The survival rates of the premenopausal, perimenopausal and postmenopausal patients were 87.0% (20/23), 92.1% (210/228) and 91.7% (77/84), respectively. The Kaplan-Meier survival curve analysis showed that there was no significant difference among the 3 groups (P>0.05). The multivariate Cox regression analysis showed that lymph node metastasis, Ki-67 positive cells ≥ 60% and low PR expression were independent prognostic factors for perimenopausal patients with ER/PR⁺HER2^- invasive breast cancer (hazard ratio=2.43, 3.45, 0.27, all P<0.05). Conclusion Perimenopausal ER/PR⁺HER2^- invasive breast cancer has its unique clinicopathological features, but there is no significant difference in the prognosis of ER/PR⁺HER2^- invasive breast cancer patients with different menopausal statuses. Lymph node metastasis, Ki-67 positive cells ≥ 60%, and low PR expression are independent prognostic factors for perimenopausal patients with ER/PR⁺HER2^- invasive breast cancer.